Celsus Therapeutics is a drug development company focusing on novel anti-inflammatory, first-in-class synthetic drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAIDs). Celsus’s proprietary drug technology platform is unique and potentially offers an answer to an urgent unmet need: the lack of satisfactory alternatives to corticosteroids in the treatment of a multitude of inflammatory diseases. The company has assembled an experienced team that shares its vision and is committed to making it a success.

Innovative Technology

Pipeline

Press Releases